Does the media prefer TNGX or RDY?

In the previous week, Dr. Reddy's Laboratories had 7 more articles in the media than Tango Therapeutics. MarketBeat recorded 9 mentions for Dr. Reddy's Laboratories and 2 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.93 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TNGX or ELAN?

In the previous week, Elanco Animal Health had 13 more articles in the media than Tango Therapeutics. MarketBeat recorded 15 mentions for Elanco Animal Health and 2 mentions for Tango Therapeutics. Elanco Animal Health's average media sentiment score of 1.18 beat Tango Therapeutics' score of 0.93 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 9 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TNGX or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 6 more articles in the media than Tango Therapeutics. MarketBeat recorded 8 mentions for Arrowhead Pharmaceuticals and 2 mentions for Tango Therapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 1.05 beat Tango Therapeutics' score of 0.93 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ABVX or TNGX more profitable?

Abivax has a net margin of 0.00% compared to Tango Therapeutics' net margin of -151.15%. Tango Therapeutics' return on equity of -41.54% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Tango Therapeutics -151.15% -41.54% -33.44%

Does the media favor ABVX or TNGX?

In the previous week, Abivax had 22 more articles in the media than Tango Therapeutics. MarketBeat recorded 24 mentions for Abivax and 2 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.93 beat Abivax's score of 0.18 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 3 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 4 Very Negative mention(s) Neutral Tango Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PRAX or TNGX?

In the previous week, Praxis Precision Medicines had 18 more articles in the media than Tango Therapeutics. MarketBeat recorded 20 mentions for Praxis Precision Medicines and 2 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.93 beat Praxis Precision Medicines' score of -0.16 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Tango Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tango Therapeutics (TNGX) Competitors

$21.54 +0.04 (+0.20%)

As of 03:15 PM Eastern

Compare

TNGX vs. RDY, ELAN, ARWR, ABVX, and PRAX

Should you buy Tango Therapeutics stock or one of its competitors? MarketBeat compares Tango Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tango Therapeutics include Dr. Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Arrowhead Pharmaceuticals (ARWR), Abivax (ABVX), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry.

How does Tango Therapeutics compare to Dr. Reddy's Laboratories?

Tango Therapeutics (NASDAQ:TNGX) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Dr. Reddy's Laboratories has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$56.99M	54.42	-$101.59M	-$0.83	N/A
Dr. Reddy's Laboratories	$335.93B	0.03	$484.20M	$0.58	22.47

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Tango Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Tango Therapeutics' net margin of -151.15%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-41.54%	-33.44%
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

In the previous week, Dr. Reddy's Laboratories had 7 more articles in the media than Tango Therapeutics. MarketBeat recorded 9 mentions for Dr. Reddy's Laboratories and 2 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.93 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tango Therapeutics currently has a consensus price target of $32.27, suggesting a potential upside of 50.52%. Dr. Reddy's Laboratories has a consensus price target of $16.90, suggesting a potential upside of 29.65%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Tango Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Tango Therapeutics and Dr. Reddy's Laboratories tied by winning 8 of the 16 factors compared between the two stocks.

How does Tango Therapeutics compare to Elanco Animal Health?

Tango Therapeutics (NASDAQ:TNGX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Elanco Animal Health has a net margin of -4.95% compared to Tango Therapeutics' net margin of -151.15%. Elanco Animal Health's return on equity of 7.42% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-41.54%	-33.44%
Elanco Animal Health	-4.95%	7.42%	3.66%

Tango Therapeutics presently has a consensus target price of $32.27, indicating a potential upside of 50.52%. Elanco Animal Health has a consensus target price of $28.20, indicating a potential upside of 15.64%. Given Tango Therapeutics' higher probable upside, equities analysts clearly believe Tango Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tango Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$56.99M	54.42	-$101.59M	-$0.83	N/A
Elanco Animal Health	$4.72B	2.58	-$232M	-$0.50	N/A

Tango Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market.

In the previous week, Elanco Animal Health had 13 more articles in the media than Tango Therapeutics. MarketBeat recorded 15 mentions for Elanco Animal Health and 2 mentions for Tango Therapeutics. Elanco Animal Health's average media sentiment score of 1.18 beat Tango Therapeutics' score of 0.93 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	9 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Elanco Animal Health beats Tango Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Tango Therapeutics compare to Arrowhead Pharmaceuticals?

Tango Therapeutics (NASDAQ:TNGX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Arrowhead Pharmaceuticals has a net margin of -48.38% compared to Tango Therapeutics' net margin of -151.15%. Tango Therapeutics' return on equity of -41.54% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-41.54%	-33.44%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Arrowhead Pharmaceuticals has higher revenue and earnings than Tango Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$56.99M	54.42	-$101.59M	-$0.83	N/A
Arrowhead Pharmaceuticals	$622.01M	16.49	-$1.63M	-$2.15	N/A

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Tango Therapeutics presently has a consensus target price of $32.27, suggesting a potential upside of 50.52%. Arrowhead Pharmaceuticals has a consensus target price of $87.80, suggesting a potential upside of 20.59%. Given Tango Therapeutics' higher probable upside, equities analysts clearly believe Tango Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
Arrowhead Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Tango Therapeutics has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

In the previous week, Arrowhead Pharmaceuticals had 6 more articles in the media than Tango Therapeutics. MarketBeat recorded 8 mentions for Arrowhead Pharmaceuticals and 2 mentions for Tango Therapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 1.05 beat Tango Therapeutics' score of 0.93 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arrowhead Pharmaceuticals beats Tango Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Tango Therapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Tango Therapeutics (NASDAQ:TNGX) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

In the previous week, Abivax had 22 more articles in the media than Tango Therapeutics. MarketBeat recorded 24 mentions for Abivax and 2 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.93 beat Abivax's score of 0.18 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	3 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	4 Very Negative mention(s)	Neutral
Tango Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Abivax has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

47.9% of Abivax shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Abivax currently has a consensus price target of $133.15, indicating a potential upside of 51.50%. Tango Therapeutics has a consensus price target of $32.27, indicating a potential upside of 50.52%. Given Abivax's stronger consensus rating and higher possible upside, research analysts clearly believe Abivax is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80
Tango Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

Tango Therapeutics has higher revenue and earnings than Abivax. Tango Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Tango Therapeutics	$56.99M	54.42	-$101.59M	-$0.83	N/A

Abivax has a net margin of 0.00% compared to Tango Therapeutics' net margin of -151.15%. Tango Therapeutics' return on equity of -41.54% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Tango Therapeutics	-151.15%	-41.54%	-33.44%

Summary

Tango Therapeutics beats Abivax on 9 of the 16 factors compared between the two stocks.

How does Tango Therapeutics compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Tango Therapeutics (NASDAQ:TNGX) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

Praxis Precision Medicines has a net margin of 0.00% compared to Tango Therapeutics' net margin of -151.15%. Tango Therapeutics' return on equity of -41.54% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Tango Therapeutics	-151.15%	-41.54%	-33.44%

Tango Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Tango Therapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	881.51	-$303.27M	-$13.37	N/A
Tango Therapeutics	$56.99M	54.42	-$101.59M	-$0.83	N/A

Praxis Precision Medicines has a beta of 2.71, meaning that its stock price is 171% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

Praxis Precision Medicines currently has a consensus target price of $572.72, indicating a potential upside of 111.86%. Tango Therapeutics has a consensus target price of $32.27, indicating a potential upside of 50.52%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, equities research analysts clearly believe Praxis Precision Medicines is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	4 Strong Buy rating(s)	2.95
Tango Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Praxis Precision Medicines had 18 more articles in the media than Tango Therapeutics. MarketBeat recorded 20 mentions for Praxis Precision Medicines and 2 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.93 beat Praxis Precision Medicines' score of -0.16 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tango Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 2.7% of Praxis Precision Medicines shares are owned by insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Praxis Precision Medicines beats Tango Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Tango Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNGX vs. The Competition

Export

Metric	Tango Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.11B	$3.27B	$6.26B	$12.43B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-25.93	17.91	22.42	24.23
Price / Sales	54.42	322.86	548.01	125.38
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	8.34	6.59	9.82	6.71
Net Income	-$101.59M	$24.20M	$3.56B	$337.09M
7 Day Performance	9.11%	-3.13%	-1.17%	0.63%
1 Month Performance	2.20%	0.44%	3.71%	5.15%
1 Year Performance	561.76%	46.70%	27.28%	34.36%

Tango Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNGX Tango Therapeutics	2.8891 of 5 stars	$21.54 +0.2%	$32.27 +49.8%	+746.5%	$3.12B	$56.99M	N/A	90
RDY Dr. Reddy's Laboratories	2.8702 of 5 stars	$13.75 +1.1%	$16.90 +22.9%	-11.6%	$11.48B	$3.58B	23.71	27,811	Analyst Revision
ELAN Elanco Animal Health	4.0025 of 5 stars	$22.51 +3.6%	$28.20 +25.3%	+76.0%	$11.24B	$4.72B	N/A	9,400	News Coverage Positive News
ARWR Arrowhead Pharmaceuticals	3.1452 of 5 stars	$76.38 +1.9%	$87.80 +15.0%	+331.8%	$10.76B	$829.45M	N/A	400	Positive News
ABVX Abivax	3.7937 of 5 stars	$125.06 +2.5%	$137.15 +9.7%	+1,041.7%	$9.97B	N/A	N/A	61	Trending News Analyst Forecast Options Volume Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNGX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tango Therapeutics (TNGX) Competitors

TNGX vs. RDY, ELAN, ARWR, ABVX, and PRAX

How does Tango Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Tango Therapeutics compare to Elanco Animal Health?

Summary

How does Tango Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Tango Therapeutics compare to Abivax?

Summary

How does Tango Therapeutics compare to Praxis Precision Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX vs. The Competition

Tango Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tango Therapeutics (TNGX) Competitors

TNGX vs. RDY, ELAN, ARWR, ABVX, and PRAX

How does Tango Therapeutics compare to Dr. Reddy's Laboratories?

Which has preferable valuation & earnings, TNGX or RDY?

Do institutionals & insiders hold more shares of TNGX or RDY?

Which has more risk and volatility, TNGX or RDY?

Is TNGX or RDY more profitable?

Does the media prefer TNGX or RDY?

Do analysts rate TNGX or RDY?

Summary

How does Tango Therapeutics compare to Elanco Animal Health?

Is TNGX or ELAN more profitable?

Do analysts recommend TNGX or ELAN?

Do insiders and institutionals believe in TNGX or ELAN?

Which has preferable valuation and earnings, TNGX or ELAN?

Which has more risk & volatility, TNGX or ELAN?

Does the media prefer TNGX or ELAN?

Summary

How does Tango Therapeutics compare to Arrowhead Pharmaceuticals?

Is TNGX or ARWR more profitable?

Which has stronger earnings & valuation, TNGX or ARWR?

Do institutionals & insiders hold more shares of TNGX or ARWR?

Do analysts recommend TNGX or ARWR?

Which has more volatility and risk, TNGX or ARWR?

Does the media prefer TNGX or ARWR?

Summary

How does Tango Therapeutics compare to Abivax?

Does the media favor ABVX or TNGX?

Which has more volatility and risk, ABVX or TNGX?

Do institutionals & insiders have more ownership in ABVX or TNGX?

Do analysts rate ABVX or TNGX?

Which has better valuation & earnings, ABVX or TNGX?

Is ABVX or TNGX more profitable?

Summary

How does Tango Therapeutics compare to Praxis Precision Medicines?

Is PRAX or TNGX more profitable?

Which has stronger earnings & valuation, PRAX or TNGX?

Which has more risk & volatility, PRAX or TNGX?

Do analysts prefer PRAX or TNGX?

Does the media refer more to PRAX or TNGX?

Do insiders and institutionals believe in PRAX or TNGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX vs. The Competition

Tango Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools